Relay Therapeutics (RLAY) Invested Capital (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Invested Capital data on file, last reported at $642.2 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $642.2 million, down 10.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $642.2 million (down 10.94% YoY), and the FY2025 annual result was $567.1 million, down 27.09% from the prior year.
• Invested Capital grew to $642.2 million in Q1 2026 per RLAY's latest filing, from $567.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $999.8 million in Q3 2022 and troughed at $567.1 million in Q4 2025.
• A 5-year average of $767.3 million and a median of $777.8 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital soared 75.06% in 2022, then retreated 27.56% in 2025.
• A 5-year view of Invested Capital shows it stood at $950.2 million in 2022, then slipped by 20.86% to $752.0 million in 2023, then climbed by 3.43% to $777.8 million in 2024, then retreated by 27.09% to $567.1 million in 2025, then climbed by 13.25% to $642.2 million in 2026.
• Business Quant data shows RLAY's Invested Capital at $642.2 million in Q1 2026, $567.1 million in Q4 2025, and $607.7 million in Q3 2025.